Agios Pharm Stock Price Prediction

AGIO Stock  USD 57.51  1.83  3.29%   
As of today The RSI of Agios Pharm's share price is above 80 . This suggests that the stock is significantly overbought by investors. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards.

Oversold Vs Overbought

82

 
Oversold
 
Overbought
The successful prediction of Agios Pharm's future price could yield a significant profit. We analyze noise-free headlines and recent hype associated with Agios Pharm, which may create opportunities for some arbitrage if properly timed. Below are the key fundamental drivers impacting Agios Pharm's stock price prediction:
EPS Estimate Next Quarter
(1.73)
EPS Estimate Current Year
11.06
EPS Estimate Next Year
(5.51)
Wall Street Target Price
53.875
EPS Estimate Current Quarter
1.11
Using Agios Pharm hype-based prediction, you can estimate the value of Agios Pharm from the perspective of Agios Pharm response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Agios Pharm to buy its stock at a price that has no basis in reality. In that case, they are not buying Agios because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.

Agios Pharm after-hype prediction price

    
  USD 57.49  
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
  
Check out Agios Pharm Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
Intrinsic
Valuation
LowRealHigh
43.5446.5063.26
Details
Naive
Forecast
LowNextHigh
49.4152.3755.33
Details
10 Analysts
Consensus
LowTargetHigh
35.4939.0043.29
Details
Earnings
Estimates (0)
LowProjected EPSHigh
2.622.772.91
Details

Agios Pharm After-Hype Price Prediction Density Analysis

As far as predicting the price of Agios Pharm at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Agios Pharm or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Agios Pharm, with the unreliable approximations that try to describe financial returns.
   Next price density   
       Expected price to next headline  

Agios Pharm Estimiated After-Hype Price Volatility

In the context of predicting Agios Pharm's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Agios Pharm's historical news coverage. Agios Pharm's after-hype downside and upside margins for the prediction period are 54.53 and 60.45, respectively. We have considered Agios Pharm's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
57.51
57.49
After-hype Price
60.45
Upside
Agios Pharm is very steady at this time. Analysis and calculation of next after-hype price of Agios Pharm is based on 3 months time horizon.

Agios Pharm Stock Price Prediction Analysis

Have you ever been surprised when a price of a Company such as Agios Pharm is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Agios Pharm backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Agios Pharm, there might be something going there, and it might present an excellent short sale opportunity.
Expected ReturnPeriod VolatilityHype ElasticityRelated ElasticityNews DensityRelated DensityExpected Hype
  0.42 
2.96
  0.03 
  0.04 
9 Events / Month
19 Events / Month
In about 9 days
Latest traded priceExpected after-news pricePotential return on next major newsAverage after-hype volatility
57.51
57.49
0.03 
4,933  
Notes

Agios Pharm Hype Timeline

Agios Pharm is presently traded for 57.51. The entity has historical hype elasticity of -0.03, and average elasticity to hype of competition of 0.04. Agios is forecasted to decline in value after the next headline, with the price expected to drop to 57.49. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.03%, whereas the daily expected return is presently at 0.42%. The volatility of related hype on Agios Pharm is about 2872.57%, with the expected price after the next announcement by competition of 57.55. About 99.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Agios Pharm recorded earning per share (EPS) of 11.66. The entity had not issued any dividends in recent years. Given the investment horizon of 90 days the next forecasted press release will be in about 9 days.
Check out Agios Pharm Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.

Agios Pharm Related Hype Analysis

Having access to credible news sources related to Agios Pharm's direct competition is more important than ever and may enhance your ability to predict Agios Pharm's future price movements. Getting to know how Agios Pharm's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Agios Pharm may potentially react to the hype associated with one of its peers.
Hype
Elasticity
News
Density
Semi
Deviation
Information
Ratio
Potential
Upside
Value
At Risk
Maximum
Drawdown
MREOMereo BioPharma Group(0.15)9 per month 0.00 (0.10) 5.14 (5.79) 19.32 
BPMCBlueprint Medicines Corp(1.72)8 per month 2.61 (0.03) 4.90 (3.62) 14.28 
DAWNDay One Biopharmaceuticals 0.23 9 per month 2.72 (0.04) 3.84 (3.69) 11.44 
BMRNBiomarin Pharmaceutical 0.62 13 per month 0.00 (0.24) 1.42 (3.32) 18.88 
IDYAIdeaya Biosciences 0.02 7 per month 0.00 (0.22) 4.15 (5.09) 15.21 
ANABAnaptysBio 0.24 7 per month 0.00 (0.15) 5.30 (7.28) 35.57 
MGTXMeiraGTx Holdings PLC(0.52)8 per month 2.49  0.13  5.71 (5.68) 21.07 
KROSKeros Therapeutics(0.79)9 per month 2.13  0.09  4.39 (4.31) 16.94 
FIXXHomology Medicines(0.01)2 per month 3.52  0.01  5.77 (5.61) 19.43 
KYMRKymera Therapeutics 1.42 10 per month 3.09 (0.04) 4.84 (4.74) 18.10 
RVMDRevolution Medicines 1.13 10 per month 2.04  0.12  4.81 (3.24) 10.95 
CCCCC4 Therapeutics(0.35)10 per month 0.00 (0.11) 9.57 (7.98) 23.66 
NRIXNurix Therapeutics 0.56 11 per month 0.00 (0.04) 6.17 (4.73) 22.77 
RLAYRelay Therapeutics(0.20)11 per month 0.00 (0.06) 4.82 (6.29) 66.18 
STOKStoke Therapeutics(0.04)10 per month 0.00 (0.09) 4.68 (6.99) 21.35 
PLRXPliant Therapeutics 0.22 9 per month 3.19 (0.02) 5.37 (5.55) 24.35 
BDTXBlack Diamond Therapeutics 0.18 7 per month 0.00 (0.30) 5.56 (8.30) 19.51 
ARVNArvinas(0.04)8 per month 3.43  0  4.85 (5.50) 17.13 
SNDXSyndax Pharmaceuticals(0.06)10 per month 0.00 (0.1) 4.02 (4.33) 34.00 
COGTCogent Biosciences 0.18 7 per month 0.00 (0.05) 4.73 (6.85) 21.15 
CGEMCullinan Oncology LLC 1.25 10 per month 0.00 (0.17) 5.88 (7.24) 17.85 
KALVKalvista Pharmaceuticals 0.34 8 per month 0.00 (0.07) 6.50 (6.22) 31.70 
MRSNMersana Therapeutics(0.14)7 per month 5.12  0.1  12.03 (9.72) 32.25 

Agios Pharm Additional Predictive Modules

Most predictive techniques to examine Agios price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Agios using various technical indicators. When you analyze Agios charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.

About Agios Pharm Predictive Indicators

The successful prediction of Agios Pharm stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Agios Pharm, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Agios Pharm based on analysis of Agios Pharm hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Agios Pharm's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Agios Pharm's related companies.
 2023 2024 (projected)
Days Sales Outstanding38.2436.11
PTB Ratio1.531.45

Story Coverage note for Agios Pharm

The number of cover stories for Agios Pharm depends on current market conditions and Agios Pharm's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Agios Pharm is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Agios Pharm's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.

Agios Pharm Short Properties

Agios Pharm's future price predictability will typically decrease when Agios Pharm's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Agios Pharm often depends not only on the future outlook of the potential Agios Pharm's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Agios Pharm's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding55.7 M
Cash And Short Term Investments776.9 M
When determining whether Agios Pharm offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Agios Pharm's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Agios Pharm Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Agios Pharm Stock:
Check out Agios Pharm Basic Forecasting Models to cross-verify your projections.
To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
11.66
Revenue Per Share
0.582
Quarterly Revenue Growth
0.212
Return On Assets
(0.18)
Return On Equity
0.5366
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.